Literature DB >> 14609807

Apolipoprotein epsilon4 allele status, depressive symptoms, and cognitive decline in middle-aged and elderly persons without dementia.

Helen Lavretsky1, Linda Ercoli, Prabha Siddarth, Susan Bookheimer, Karen Miller, Gary Small.   

Abstract

OBJECTIVE: Because the apolipoprotein epsilon4 (APOE-epsilon4) allele or depressive symptoms may increase the risk for development of Alzheimer disease (AD), the authors assessed APOE-epsilon4 status, baseline level of depressive symptoms, and subsequent cognitive decline in middle-aged and older persons without dementia.
METHODS: The 49 subjects (age range: 51-85 years) included 20 with and 29 without APOE-epsilon4. Baseline and follow-up neuropsychological assessments determined the degree of cognitive decline.
RESULTS: Baseline mild depressive symptoms were greater in APOE-epsilon4 carriers than in non-carriers. The subject groups demonstrated significant cognitive decline at follow-up. APOE-epsilon4 carriers showed a significantly greater rate of verbal memory decline than non-carriers. Baseline depressive symptoms, however, did not predict future cognitive decline.
CONCLUSIONS: These results suggest that APOE-epsilon4 carriers may have a greater severity of depressive symptoms than non-carriers. The APOE-epsilon4 allele (but not baseline mild depressive symptoms) is associated with verbal memory decline in middle-aged and older persons. Because of the limited range of depression scores in our sample, these findings should be interpreted with caution and not be generalized to patients with syndromal depression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14609807      PMCID: PMC2810950          DOI: 10.1176/appi.ajgp.11.6.667

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  39 in total

1.  Memory performance in healthy elderly without Alzheimer's disease: effects of time and apolipoprotein-E.

Authors:  R Mayeux; S A Small; M Tang; B Tycko; Y Stern
Journal:  Neurobiol Aging       Date:  2001 Jul-Aug       Impact factor: 4.673

2.  Depression, APOE genotype and subjective memory impairment: a cross-sectional study in an African-Caribbean population.

Authors:  R Stewart; C Russ; M Richards; C Brayne; S Lovestone; A Mann
Journal:  Psychol Med       Date:  2001-04       Impact factor: 7.723

3.  Memory decline in healthy older people: implications for identifying mild cognitive impairment.

Authors:  A Collie; P Maruff; R Shafiq-Antonacci; M Smith; M Hallup; P R Schofield; C L Masters; J Currie
Journal:  Neurology       Date:  2001-06-12       Impact factor: 9.910

4.  Association of the apolipoprotein E epsilon4 allele with late-onset depression.

Authors:  A S Rigaud; L Traykov; L Caputo; J Coste; F Latour; R Couderc; F Moulin; F Boller; F Forette
Journal:  Neuroepidemiology       Date:  2001-10       Impact factor: 3.282

5.  Memory self-appraisal and depressive symptoms in people at genetic risk for Alzheimer's disease.

Authors:  G W Small; S T Chen; S Komo; L Ercoli; K Miller; P Siddarth; A Kaplan; D Dorsey; H Lavretsky; S Saxena; S Y Bookheimer
Journal:  Int J Geriatr Psychiatry       Date:  2001-11       Impact factor: 3.485

6.  Polymorphisms in the apolipoprotein E (APOE) gene in gerontopsychiatric patients.

Authors:  P Zill; R Engel; H Hampel; S Behrens; K Bürger; F Padberg; S Stübner; H J Möller; M Ackenheil; B Bondy
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2001       Impact factor: 5.270

7.  A longitudinal study of apolipoprotein-E genotype and depressive symptoms in community-dwelling older adults.

Authors:  M Mauricio; R O'Hara; J A Yesavage; L Friedman; H C Kraemer; M Van De Water; G M Murphy
Journal:  Am J Geriatr Psychiatry       Date:  2000       Impact factor: 4.105

8.  Apolipoprotein-E and white-matter hyperintensities in late-life depression.

Authors:  H Lavretsky; I M Lesser; M Wohl; B L Miller; C M Mehringer; H V Vinters
Journal:  Am J Geriatr Psychiatry       Date:  2000       Impact factor: 4.105

9.  Preclinical cognitive decline in late middle-aged asymptomatic apolipoprotein E-e4/4 homozygotes: a replication study.

Authors:  R J Caselli; D Osborne; E M Reiman; J G Hentz; C J Barbieri; A M Saunders; J Hardy; N R Graff-Radford; G R Hall; G E Alexander
Journal:  J Neurol Sci       Date:  2001-08-15       Impact factor: 3.181

10.  [Apolipoprotein E4 and memory decline in the elderly].

Authors:  C Jonker; M G Dik; G J van Kamp; D J Deeg
Journal:  Tijdschr Gerontol Geriatr       Date:  2000-10
View more
  16 in total

1.  Relationships Between Cognitive Complaints and Quality of Life in Older Adults With Mild Cognitive Impairment, Mild Alzheimer Disease Dementia, and Normal Cognition.

Authors:  Shana D Stites; Kristin Harkins; Jonathan D Rubright; Jason Karlawish
Journal:  Alzheimer Dis Assoc Disord       Date:  2018 Oct-Dec       Impact factor: 2.703

2.  Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis.

Authors:  Raymond L Ownby; Elizabeth Crocco; Amarilis Acevedo; Vineeth John; David Loewenstein
Journal:  Arch Gen Psychiatry       Date:  2006-05

3.  Anxiety and verbal memory performance in APOE-4 carriers and noncarriers aged 50 years and above.

Authors:  Ashley R Curiel; Karen J Miller; Karen Pollard; Jeanne Kim; Jena Kravitz; Gary W Small
Journal:  Aging health       Date:  2012-02-01

4.  APOE-epsilon4, depressive symptoms, and cognitive decline in Chinese older adults: Singapore Longitudinal Aging Studies.

Authors:  Mathew Niti; Keng-Bee Yap; Ee-Heok Kua; Tze-Pin Ng
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-01-30       Impact factor: 6.053

5.  Depression and anxiety symptoms are associated with cerebral FDDNP-PET binding in middle-aged and older nondemented adults.

Authors:  Helen Lavretsky; Prabha Siddarth; Vladimir Kepe; Linda M Ercoli; Karen J Miller; Alison C Burggren; Susan Y Bookheimer; Sung-Cheng Huang; Jorge R Barrio; Gary W Small
Journal:  Am J Geriatr Psychiatry       Date:  2009-06       Impact factor: 4.105

6.  Resolving the relationship between ApolipoproteinE and depression.

Authors:  Michael A Slifer; Eden R Martin; John R Gilbert; Jonathan L Haines; Margaret A Pericak-Vance
Journal:  Neurosci Lett       Date:  2009-03-06       Impact factor: 3.046

7.  Stopping Cognitive Decline in Patients With Late-Life Depression: A New Front in the Fight Against Dementia.

Authors:  Eric J Lenze; Aristotle N Voineskos; Meryl A Butters; Jordan F Karp
Journal:  Am J Geriatr Psychiatry       Date:  2018-06-05       Impact factor: 4.105

8.  Depressive symptoms moderate the influence of the apolipoproteine epsilon4 allele on cognitive decline in a sample of community dwelling older adults.

Authors:  Elizabeth A Corsentino; Kathryn Sawyer; Natalie Sachs-Ericsson; Dan G Blazer
Journal:  Am J Geriatr Psychiatry       Date:  2009-02       Impact factor: 4.105

9.  ApoE alleles, depression and positive affect in multiple sclerosis.

Authors:  L J Julian; L Vella; D Frankel; S L Minden; J R Oksenberg; D C Mohr
Journal:  Mult Scler       Date:  2009-03       Impact factor: 6.312

10.  APOE ε4 associated with preserved executive function performance and maintenance of temporal and cingulate brain volumes in younger adults.

Authors:  Warren D Taylor; Brian Boyd; Rachel Turner; Douglas R McQuoid; Allison Ashley-Koch; James R MacFall; Ayman Saleh; Guy G Potter
Journal:  Brain Imaging Behav       Date:  2017-02       Impact factor: 3.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.